|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003873,
umls-concept:C0030705,
umls-concept:C0086860,
umls-concept:C0441889,
umls-concept:C0871261,
umls-concept:C1122087,
umls-concept:C1319635,
umls-concept:C1456820,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1882417,
umls-concept:C2003941,
umls-concept:C2911692
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2007-3-8
|
|
pubmed:abstractText |
To investigate the influence of -308 tumour necrosis factor-alpha (TNFalpha) promoter polymorphism and circulating TNFalpha levels in the clinical response to adalimumab treatment in patients with rheumatoid arthritis (RA).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0300-9742
|
|
pubmed:author |
pubmed-author:AguillónJ CJC,
pubmed-author:AlamoMM,
pubmed-author:CatalanDD,
pubmed-author:CuchacovichMM,
pubmed-author:EdwardesMM,
pubmed-author:FuentealbaCC,
pubmed-author:GaticaHH,
pubmed-author:GutierrezMM,
pubmed-author:LlanosCC,
pubmed-author:PachecoDD,
pubmed-author:SabugoFF,
pubmed-author:Salazar-OnfrayFF,
pubmed-author:SalazaroLL,
pubmed-author:SchiattinoII,
pubmed-author:SotoLL,
pubmed-author:ValenzuelaOO,
pubmed-author:VillanuevaLL
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
35
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
435-40
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17343250-Adult,
pubmed-meshheading:17343250-Antibodies, Monoclonal,
pubmed-meshheading:17343250-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17343250-Antirheumatic Agents,
pubmed-meshheading:17343250-Arthritis, Rheumatoid,
pubmed-meshheading:17343250-Chile,
pubmed-meshheading:17343250-Genotype,
pubmed-meshheading:17343250-Humans,
pubmed-meshheading:17343250-Middle Aged,
pubmed-meshheading:17343250-Polymorphism, Single Nucleotide,
pubmed-meshheading:17343250-Promoter Regions, Genetic,
pubmed-meshheading:17343250-Time Factors,
pubmed-meshheading:17343250-Treatment Outcome,
pubmed-meshheading:17343250-Tumor Necrosis Factor-alpha
|
|
pubmed:articleTitle |
Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis.
|
|
pubmed:affiliation |
Rheumatology Section, Department of Medicine, Clinical Hospital University of Chile, Santiago. mcuchaco@yahoo.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
